China Universal Asset Management Co. Ltd. Purchases Shares of 15,396 Biohaven Ltd. (NYSE:BHVN)

China Universal Asset Management Co. Ltd. acquired a new position in shares of Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,396 shares of the company’s stock, valued at approximately $575,000.

A number of other institutional investors and hedge funds also recently modified their holdings of BHVN. nVerses Capital LLC acquired a new position in shares of Biohaven in the third quarter valued at $50,000. Values First Advisors Inc. acquired a new position in Biohaven in the 3rd quarter valued at about $78,000. US Bancorp DE raised its holdings in Biohaven by 57.1% in the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company’s stock valued at $109,000 after acquiring an additional 790 shares during the period. KBC Group NV lifted its position in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after acquiring an additional 443 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in shares of Biohaven by 19.1% during the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock worth $156,000 after acquiring an additional 500 shares during the period. 88.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 target price (up previously from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. HC Wainwright reissued a “buy” rating and issued a $59.00 target price on shares of Biohaven in a research report on Tuesday, December 17th. TD Cowen upped their price target on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. Thirteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $63.00.

Insiders Place Their Bets

In related news, Director John W. Childs bought 29,000 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the purchase, the director now owns 2,368,741 shares in the company, valued at $85,132,551.54. This represents a 1.24 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 16.00% of the company’s stock.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $38.30 on Monday. Biohaven Ltd. has a 1 year low of $26.80 and a 1 year high of $62.21. The stock has a market capitalization of $3.87 billion, a price-to-earnings ratio of -4.10 and a beta of 1.29. The company’s 50 day simple moving average is $39.65 and its 200 day simple moving average is $42.57.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, analysts anticipate that Biohaven Ltd. will post -8.85 EPS for the current fiscal year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.